shutterstock_492675739_mdart10
7 May 2021PatentsAlex Baldwin

Federal Circuit overturns L’Oreal’s $66m haircare patent loss

L’Oreal has convinced the Federal Circuit to partially reverse a district court ruling ordering it to pay $66 million for infringing two patents and stealing trade secrets from cosmetics startup Olaplex.

The Federal Circuit found that the trade secrets that the beauty giant was accused to have stolen from Olaplex were “not secret” and called for a retrial for the infringement of one of the patents in a non-precedential decision published yesterday, April 6.

Olaplex’s cross-appeal for non-patent damages was denied due to the Federal Circuit’s reversal of non-patent liability in the proceedings.

L’Oreal’s request to reassign proceedings to a different district court judge was also denied.

Action against L’Oreal was first brought by Liqwd, who had all of its interest transferred to fellow plaintiff Olaplex in January 2020.

In August 2019 a jury at the US District Court for the District of Delaware ruled in favour of Olaplex, finding L’Oreal guilty of infringing two hair treatment patents (US9,498,419 and US9,668,954) and of misappropriation of several trade secrets.

The jury determined that Olaplex was entitled to nearly $100 million in damages. Judge Bataillon then ruled that Olaplex was only entitled to $66.2 million in total.

The judge also granted a permanent injunction preventing L’Oreal from selling the infringing ‘Smartbond’ products.

The majority of claims of the two patents L’Oreal had been accused of infringing were invalidated in earlier proceedings by the Patent Trial and Appeal Board (PTAB ), leaving only claims related to methods for reducing ‘breakage’ from a single hair bleaching session.

The PTAB found claims 1–13, 19–23, and 29–30 of the Olaplex patent (US number 9,668,954) to be invalid as obvious.

L’Oreal USA appealed the district court ruling to the Federal Circuit and Olaplex filed a notice of cross-appeal.

In prior Federal Circuit proceedings, both L'Oréal and Olaplex failed to convince the court to overturn the decision related to the patent treatments, upholding the PTAB decision which invalidated key claims of both the patents, but maintaining other claims of the patents were still valid.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox

Today’s top stories

Ericsson and Samsung agree SEP truce

US backs COVID IP waiver - Industry reacts

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Patents
27 April 2022   The effects of the ‘skinny label’ decision are still being felt across pharma. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch revisits GSK v Teva.
Trademarks
14 November 2022   A case involving L’Oréal has clarified the General Court’s position on protection for single letter marks, explains Henrike Strobl of Nordemann.
Patents
13 July 2022   The pharmaceuticals and life sciences partner will serve a one-year term as leader of the organisation.